Pipeline

Xeris is interested in establishing a portfolio of strategic collaborations with key partners who wish to co-develop products using Xeris’ platform technologies (XeriSol™ and XeriJect^®). Currently, Xeris is working on a number of formulation feasibility programs for its own as well as its partners’ pipeline in the areas of small molecules, peptides, biologics, and monoclonal antibodies. We welcome the opportunity to discuss areas of potential common interest upon which to build value for both parties. To discuss partnering opportunities, please contact us.

Product Candidate	Indication	Pre-Clinical Phase 1 Phase 2 Phase 3 Marketed
Gvoke® (US) (glucagon injection)	Severe Hypoglycemia info	PreClinical Phase 1 Phase 2 Phase 3 Marketed	Severe hypoglycemia, or severe low blood sugar, occurs when your blood sugar gets so low that you need help to bring it back up. Sometimes people with very low blood sugar may have a hard time thinking straight or controlling their body, get very tired, refuse to eat, pass out, or even have a seizure. It is an emergency situation that needs to be treated immediately.^* ^{* National Institute of Diabetes and Digestive and Kidney Diseases. Low blood glucose (hypoglycemia). Updated July 2021. Accessed September 21, 2023. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia}
Keveyis® (dichlorphenamide)	Primary Periodic Paralysis† info	PreClinical Phase 1 Phase 2 Phase 3 Marketed	Primary Periodic Paralysis (PPP) is a rare genetic condition that affects muscles and causes episodes of muscle weakness and/or temporary paralysis, that can be progressive and debilitating. ^1,2 ¹ Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57:522-530. ² Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126-133.
Ogluo® (UK/EU)** (glucagon)	Severe Hypoglycemia info	PreClinical Phase 1 Phase 2 Phase 3 Marketed	Severe hypoglycemia, or severe low blood sugar, occurs when your blood sugar gets so low that you need help to bring it back up. Sometimes people with very low blood sugar may have a hard time thinking straight or controlling their body, get very tired, refuse to eat, pass out, or even have a seizure. It is an emergency situation that needs to be treated immediately. ^* ^{* National Institute of Diabetes and Digestive and Kidney Diseases. Low blood glucose (hypoglycemia). Updated July 2021. Accessed September 21, 2023. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia}
Recorlev® (levoketoconazole)	Endogenous Cushing's Syndrome† info	PreClinical Phase 1 Phase 2 Phase 3 Marketed	Endogenous CS is a rare, serious endocrine disorder caused by chronic exposure to elevated levels of cortisol; left untreated, it can be fatal. Often the result of a benign tumor of the pituitary gland that tells the body to overproduce high levels of cortisol for a sustained period of time. CS results in physical and emotional signs and symptoms that are debilitating for those living with CS. It is most common among adults aged 30 to 50 years and is more prevalent in females, accounting for 70% of cases.^* ^* The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center. Cushing’s Syndrome. Accessed Sept. 21, 2023. https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome.
Levothyroxine	Endocrinology: Hypothyroidism info	PreClinical Phase 1 Phase 2 Phase 3 Marketed	Hypothyroidism, also known as underactive thyroid disease, is a condition in which the thyroid gland does not create and release enough thyroid hormone into the bloodstream. Hypothyroidism may not cause noticeable symptoms in the early stages. Over time, untreated hypothyroidism can cause a number of health problems. *Patil N, Rehman A, Jialal I. Hypothyroidism. In: StatPearls. Updated August 8, 2023. Accessed September 26, 2023. https://www.ncbi.nlm.nih.gov/books/NBK519536/

† Orphan Drug Designation
**Xeris has an exclusive agreement with Tetris Pharma Limited, a subsidiary of Arecor Therapeutics plc, for the commercialization of Ogluo® in the European Economic Area, United Kingdom, and Switzerland